Cellavita-hd (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
8 | Huntington disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04219241 (ClinicalTrials.gov) | January 2020 | 11/12/2019 | Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients. | Clinical Extension Study for Assessing the Safety and Efficacy of the Intravenous Administration of Cellavita-HD in Huntington's Disease Patients Who Participated in the ADORE-DH Study. | Huntington Disease | Biological: Cellavita-HD | Azidus Brasil | Cellavita Pesquisa CientÃfica Ltda | Not yet recruiting | 21 Years | 65 Years | All | 35 | Phase 2;Phase 3 | Brazil |